SCHEMBL6837253

SCHEMBL6837253

CCC1OC(=O)N(Cc2ccc(NC(=O)c3ccccn3)cc2)N=C1c1ccc(OC)c(OC(F)F)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
MAPT P10636 2/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
KDM4E B2RXH2 1/20 0.44
GRM4 Q14833 7/20 0.41
HDAC6 Q9UBN7 1/20 0.40
AURKB Q96GD4 1/20 0.39
PDE4A P27815 6/20 0.39
PDE4B Q07343 6/20 0.39
PDE4C Q08493 6/20 0.39
PDE4D Q08499 6/20 0.39
PKM P14618 1/20 0.38
CD274 Q9NZQ7 1/20 0.38
CFTR P13569 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6654732 0.97 SMN1; SMN2 (0.45) SMN1; SMN2NPC1RAB9AMAPTNFKB1
SCHEMBL6658037 0.93 PDE4D (0.39) SMN1; SMN2NPC1RAB9AMAPTNFKB1
SCHEMBL6654824 0.93 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9AMAPTKDM4E
SCHEMBL6659020 0.92 NPC1 (0.42) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL6659309 0.91 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9AMAPTKDM4E
SCHEMBL6657420 0.91 SMN1; SMN2 (0.47) SMN1; SMN2NPC1RAB9AMAPTKDM4E
SCHEMBL6659619 0.91 PDE4D (0.39) SMN1; SMN2NPC1RAB9AMAPTNFKB1
SCHEMBL6658940 0.90 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9AMAPTKDM4E
SCHEMBL6842648 0.90 SMN1; SMN2 (0.44) SMN1; SMN2NPC1RAB9AMAPTKDM4E
SCHEMBL6837202 0.90 SMN1; SMN2 (0.47) SMN1; SMN2NPC1RAB9AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US disclosed
EP-0763534-B1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GMBH (DE) 2003-02-26 EP disclosed
US-5859008-A Arylalkyl diazinones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-01-12 US disclosed
EP-0763534-A1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GmbH (DE) 1997-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B SMN1; SMN2 2642/4885NPC1 3307/4885RAB9A 2053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.